Evidence map›Paper›PMID 30603638›Full record

ArticleAnnals of translational medicine2018

Surgical approach for Siewert type II adenocarcinoma of the esophagogastric junction: transthoracic or transabdominal? -a single-center retrospective study.

Zi-Feng Yang, De-Qing Wu, Jun-Jiang Wang, Xing-Yu Feng, Jia-Bin Zheng, Wei-Xian Hu, Yong Li

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zi-Feng YangGeneral Surgery Department, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
De-Qing WuGeneral Surgery Department, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Jun-Jiang WangGeneral Surgery Department, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Xing-Yu FengGeneral Surgery Department, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Jia-Bin ZhengGeneral Surgery Department, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Wei-Xian HuGeneral Surgery Department, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Yong LiGeneral Surgery Department, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Guangdong General Hospital · CNGuangdong Academy of Medical Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe surgical approach (transthoracic or transabdominal) for patients with Siewert type II adenocarcinoma of the esophagogastric junction (AEG) still remains controversial.

methodsData of patients with Siewert type II AEG were collected in the Guangdong General Hospital from 2004 to 2014 and we compared their clinicopathological outcome and prognosis in regard to the transthoracic (TT) and transabdominal (TA) approach.

resultsA total of 158 patients with Siewert type II AEG were analyzed and our results demonstrated that their overall medium survival was 52 months. Also, their 5-year overall survival rate was 39.1%, which was comparable between the TT and TA group (35.1%

conclusionsFor patients with Siewert type II AEG, the TA approach is more suitable to achieve an optimal extent of lymph node dissection, reduction in the incidence of complication, shorten hospital stay, and to promote the recovery.

Indexed as

Adenocarcinoma of the esophagogastric junction (AEG)Siewert type IIsurgical approach

Identifiers

PMID30603638
PMCPMC6312814
OpenAlexW2899638244

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.